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Introduction {#sec001}
============

Programmed cell death-1 (*PD-1*), a member of the CD28/B7 superfamily of costimulatory molecules, is expressed on activated CD4+ and CD8+ T cells, natural killer T (NKT) cells, B cells, activated monocytes and some dendritic cell (DC) \[[@pone.0152448.ref001]\]. The human gene encoding *PD-1* is located on chromosome 2q37.3, which encodes a 50--55 kD type I transmembranous glycoprotein protein \[[@pone.0152448.ref002], [@pone.0152448.ref003]\]. The *PD-1* is consisted of an immunoglobulin-like extracellular domain, and a cytoplasmic domain containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) \[[@pone.0152448.ref004]\]. *PD-1* has been well characterized as a negative regulator of T cells, and when interacts with its two ligands PD-L1 (B7-H1) and PD-L2 (B7-DC), it can strongly inhibit both proliferation and cytokine production by CD4 and CD8 T lymphocytes \[[@pone.0152448.ref005], [@pone.0152448.ref006]\]. PD-L1 has been reported to be expressed on a variety of tumor tissues or cell lines, including breast cancer, cervical cancer, gastric carcinoma, esophageal cancer and laryngocarcinoma \[[@pone.0152448.ref007]--[@pone.0152448.ref011]\]. In addition, *PD-1* is importantly involved in the regulation of regulatory T-cells (Treg) function in cancer patients. Recently, some studies have revealed a direct relation between *PD-1* blockade and down-regulation of intracellular FoxP3 expression by Treg to correct immune escape in various types of tumors \[[@pone.0152448.ref012]--[@pone.0152448.ref014]\]. Based on the inhibitory role of *PD-1* in anti-tumor responses, we considered the *PD-1* gene (Gene bank ID: 5133) as a powerful candidate for genetic susceptibilities of individuals to cancers. Previous, most studies researched about the association between the *PD-1* polymorphisms and several autoimmune diseases, including type 1 diabetes (T1D), ankylosing spondylitis (AS), SLE and rheumatoid arthritis (RA) \[[@pone.0152448.ref015]--[@pone.0152448.ref018]\]. In recent years, some studies have been changed the focus on the role of *PD-1* polymorphisms in various types of cancer patients. To date, several single nucleotide polymorphisms (SNPs) have been reported for the *PD-1* susceptibility of cancers in literature, such as *PD-1*.*5* (rs2227981), *PD-1*.*9* (rs2227982), *PD-1* rs7421861 and *PD-1*.*3* (rs11568821) et al. However, the association between the *PD-1* polymorphisms and cancer risk is inconsistent. To clarify this issue, we performed a meta-analysis from all eligible studies, to assess the association of the *PD-1* polymorphism with cancer risk.

Materials and Methods {#sec002}
=====================

Primary search strategy and Inclusion Criteria {#sec003}
----------------------------------------------

We identified all studies reporting the relationship between *PD-1* polymorphisms and cancers published before December 22, 2015 by electronically searches. The databases include Pubmed, EMBASE, the Cochrane Library database, Google Scholar, China National Knowledge Infrastructure (CNKI) and Wan Fang. The search strategies were based on combinations of the following key words: (''Programmed death-1" or ''*PD-1*") and (''cancer" or ''carcinoma") and (''gene" or ''allele" or ''genotype" or ''mutation" or ''variant" or ''variation" or ''polymorphism"), without any restriction on language. The reference lists of reviews and retrieved articles were also searched by hand for additional articles. We did not enroll abstracts or unpublished studies. For inclusion, the studies must have met the following criteria: (1) studied on human beings; (2) clear objective in the relation between *PD-1* polymorphisms and cancer; (3) case-control study, regardless of sample size, using a hospital-based or a population-based design; (4) sufficient published data about the size of the sample, odds ratio (OR), and their 95% confidence intervals (CIs).

Data Extraction {#sec004}
---------------

Data were carefully and independently extracted from all eligible publications by three of the authors (Wenjing Dong, Zhirong Shi and Jianjun Xiao). Any disagreement was resolved by discussion among the authors. All eligible data were listed in [Table 1](#pone.0152448.t001){ref-type="table"}: the surname of the first author, date of publication, quality scores, ethnicity, sources of controls, number of cases and controls and the P value of Hardy-Weinberg Equilibrium (*HWE*). Different ethnicities were categorized as Asian and Caucasian. Study designs were stratified to population-based studies and hospital-based studies.

10.1371/journal.pone.0152448.t001

###### Characteristics of eligible studies in the meta-analysis of *PD-1* polymorphisms and cancer risk.

![](pone.0152448.t001){#pone.0152448.t001g}

  Author                        Year    Quality scores   Ethnicity    Cancer type         Design   Case total       CC       CT       TT       Control total       CC       CT       TT       *P* HWE
  ----------------------------- ------- ---------------- ------------ ------------------- -------- ---------------- -------- -------- -------- ------------------- -------- -------- -------- ---------
  ***PD-1*.*5* (rs2227981)**                                                                                                                                                                  
  Ivansson EL                   2010    6                Caucasians   cervical cancer     PB       1300             471      603      226      810                 257      375      178      0.064
  Haghshenas MR                 2011    6                Asians       breast cancer       PB       435              194      191      50       328                 137      145      46       0.446
  Zhang H                       2011    6                Asians       breast cancer       PB       486              295      169      22       478                 244      210      24       0.012
  Mojtahedi Z                   2012a   6                Asians       colon cancer        PB       175              47       102      26       200                 75       89       36       0.290
  Mojtahedi Z                   2012b   6                Asians       rectal cancer       PB       25               12       7        6        200                 75       89       36       0.290
  Savabkar S                    2013    5                Asians       gastric cancer      HB       122              50       66       6        166                 89       70       7        0.136
  Yin L                         2014    7                Asians       lung cancer         PB       324              198      106      20       330                 181      105      44       0.000
  Ma Y                          2015    6                Asians       lung cancer         PB       528              244      216      68       600                 256      246      98       0.004
  ***PD-1*.*9* (rs2227982)**                                                                       **Case total**   **CC**   **CT**   **TT**   **Control total**   **CC**   **CT**   **TT**   
  Zhang H                       2011    6                Asians       breast cancer       PB       487              111      249      127      506                 95       268      143      0.121
  Qiu H                         2014    6                Asians       esophageal cancer   HB       616              159      303      154      681                 189      325      167      0.245
  Tang WF                       2015    6                Asians       gastric cancer      HB       330              75       168      87       603                 163      292      148      0.448
  Ma Y                          2015    6                Asians       lung cancer         PB       528              343      148      37       600                 404      168      28       0.056
  ***PD-1* rs7421861**                                                                             **Case total**   **TT**   **CT**   **CC**   **Control total**   **TT**   **CT**   **CC**   
  Zhang H                       2011    6                Asians       breast cancer       PB       490              333      146      11       512                 370      130      12       0.885
  Qiu H                         2014    6                Asians       esophageal cancer   HB       600              411      168      21       673                 460      188      25       0.295
  Tang WF                       2015    6                Asians       gastric cancer      HB       324              226      91       7        598                 408      168      22       0.368
  Ge J                          2015a   5                Asians       colon cancer        HB       199              133      60       6        620                 440      163      17       0.685
  Ge J                          2015b   5                Asians       rectal cancer       HB       362              241      114      7        620                 440      163      17       0.685
  ***PD-1*.*3* (rs11568821)**                                                                      **Case total**   **GG**   **GA**   **AA**   **Control total**   **GG**   **GA**   **AA**   
  Haghshenas MR                 2011    6                Asians       breast cancer       PB       436              365      63       8        290                 231      55       4        0.726
  Bayram S                      2012    7                Asians       liver cancer        PB       236              191      45       0        236                 180      56       0        0.039
  Yousefi AR                    2013    6                Asians       colon cancer        PB       80               18       27       35       110                 43       45       22       0.114
  Ma Y                          2015    6                Asians       lung cancer         PB       528              426      102      0        600                 456      142      2        0.009

PB, population-based controls; HB, hospital-based controls; *HWE*, Hardy--Weinberg equilibrium.

Quality assessment {#sec005}
------------------

Three authors (Wenjing Dong, Zhirong Shi and Jianjun Xiao) assessed the study quality independently using the Newcastle-Ottawa Scale which is a star rating system \[[@pone.0152448.ref019]\]. Nine stars are defined as the full score, and 5 to 9 stars are usually considered to be a high methodological quality while 0 to 4 stars are considered to be a poor quality \[[@pone.0152448.ref020]\]. The quality of all enrolled studies was showed in [Table 2](#pone.0152448.t002){ref-type="table"}. Any disagreements on the NOS score of the studies were resolved by discussion between the authors and our meta-analysis only enrolled high quality studies.

10.1371/journal.pone.0152448.t002

###### Quality assessment based on the Newcastle-Ottawa Scale of studies included in this meta-analysis[^a^](#t002fn001){ref-type="table-fn"}.
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  Author          Year   Adequate definition of case   Representativeness of cases   Selection of control   Definition of control   Control for important factor or additional factor[^b^](#t002fn002){ref-type="table-fn"}   Exposure assessment   Same method of ascertainment for cases and controls   Nonresponse rate   Total quality scores
  --------------- ------ ----------------------------- ----------------------------- ---------------------- ----------------------- ----------------------------------------------------------------------------------------- --------------------- ----------------------------------------------------- ------------------ ----------------------
  Ivansson EL     2010   ★                             ★                             ★                      ★                       ★                                                                                                               ★                                                                        6
  Zhang H         2011   ★                             ★                             ★                      ★                       ★                                                                                                               ★                                                                        6
  Haghshenas MR   2011   ★                             ★                             ★                      ★                       ★                                                                                                               ★                                                                        6
  Mojtahedi Z     2012   ★                             ★                             ★                      ★                       ★                                                                                                               ★                                                                        6
  Bayram S        2012   ★                             ★                             ★                      ★                       ★★                                                                                                              ★                                                                        7
  Savabkar S      2013   ★                             ★                                                    ★                       ★                                                                                                               ★                                                                        5
  Yousefi AR      2013   ★                             ★                             ★                      ★                       ★                                                                                                               ★                                                                        6
  Yin L           2014   ★                             ★                             ★                      ★                       ★★                                                                                                              ★                                                                        7
  Qiu H           2014   ★                             ★                                                    ★                       ★★                                                                                                              ★                                                                        6
  Ma Y            2015   ★                             ★                             ★                      ★                       ★                                                                                                               ★                                                                        6
  Tang WF         2015   ★                             ★                                                    ★                       ★★                                                                                                              ★                                                                        6
  Ge J            2015   ★                             ★                                                    ★                       ★                                                                                                               ★                                                                        5

^a^A study can be awarded a maximum of one star for each numbered item except for the item Control for important factor or additional factor.

^b^A maximum of two stars can be awarded for Control for important factor or additional factor.

Statistical Analysis {#sec006}
--------------------

Crude ORs with corresponding 95% CIs were used to estimate the strength of the association between the *PD-1* polymorphisms and cancer risk. The significance of the pooled OR was determined by the *Z* test and *P* (two-tailed) \<0.05 was considered statistically significant. Hardy-Weinberg equilibrium (*HWE*) in controls was calculated by chi-square test and *P*\<0.05 signified a departure from *HWE*. Between-study heterogeneity was calculated by the *I*^*2*^ test. If the heterogeneity was statistically significant (*I*^*2*^\>50%) \[[@pone.0152448.ref021]\], a random effect model (the DerSimonian and Laird method) \[[@pone.0152448.ref022]\] was used; otherwise, a fixed effect model (the Mantel-Haenszel method) \[[@pone.0152448.ref023]\] was applied. Subgroup analyses were performed by ethnicity and the control sources. The funnel plot and Egger's test were both used to examine the publication bias. For the interpretation of Egger's test, statistical significance was defined as *P*\<0.05 \[[@pone.0152448.ref024]\].The statistical analysis was performed with STATA statistical software (Version 12.0; Stata Corporation, College Station, TX, USA).

Results {#sec007}
=======

Study characteristics {#sec008}
---------------------

Five hundred and sixty-eight studies were retrieved after searching and screening based on our literature search strategy. There were 18 studies left when the irrelevant studies were excluded. Out of these, 14 studies had analyzed the association between the *PD-1* polymorphisms and cancers. After data extraction, one article \[[@pone.0152448.ref025]\] was excluded because of without control group while another one \[[@pone.0152448.ref026]\] was excluded as discussed about the gestational trophoblastic neoplasms, which contain both benign and malignant tumors. Hence we obtained 12 relevant studies that examined the association between the *PD-1* polymorphisms and cancer risk ([Fig 1](#pone.0152448.g001){ref-type="fig"}) \[[@pone.0152448.ref027]--[@pone.0152448.ref038]\]. All of them were evaluated by Newcastle-Ottawa Scale and met the high quality ([Table 2](#pone.0152448.t002){ref-type="table"}). Overall, the meta-analysis included 5,206 cancer patients and 5,174 controls from 12 articles. The information extracted from all eligible articles was summarized in [Table 1](#pone.0152448.t001){ref-type="table"}. All articles we included were case-control studies. Among them, breast cancer, gastric cancer, colorectal cancer and lung cancer are studied by two articles, respectively. The rest four studies are colon, esophageal, cervical and liver cancer study, respectively. Out of the 12 studies, 7 studies focused on the *PD-1*.*5* (rs2227981), while the *PD-1*.*9* (rs2227982), *PD-1* rs7421861 and *PD-1*.*3*(rs11568821) were all discussed in 4 studies, respectively. Among the 12 studies included in the meta-analysis, there were 11 studies of Asians and 1 study of Caucasians. According to the control source, only 4 were hospital-based researches, the rest 8 were population-based researches.

![Flow diagram of study selection.](pone.0152448.g001){#pone.0152448.g001}

*PD-1*.*5* (rs2227981) {#sec009}
----------------------

Data from seven studies which including 3,395 cases and 2,912 controls researched about the *PD-1*.*5* (rs2227981) were pooled together. Six of the studies were population-based and only one study was hospital-based. According to the ethnicity, six articles were researched about Asians and one study was about Caucasians. We conducted analyses for all genetic models and allele in overall group, Asians subgroup and population-based subgroup. Overall, we obtained significantly decreased cancer risks both in TT vs. CC (OR = 0.72, 95% CIs: 0.62--0.85, P = 0.000, *I*^*2*^ = 14.0%), TT vs. CT+CC (OR = 0.75, 95% CIs: 0.65--0.87, P = 0.000, *I*^*2*^ = 0.0%) genetic models and T vs. C (OR = 0.88, 95% CIs: 0.78--0.99, P = 0.04, *I*^*2*^ = 53.6%) allele. However, no dramatic associations were found in the other genetic models (TT+CT vs. CC: OR = 0.91, 95% CIs: 0.75--1.10, P = 0.343, *I*^*2*^ = 65.6%; TC vs. CC: OR = 0.97, 95% CIs: 0.78--1.19, P = 0.759, *I*^*2*^ = 68.2%) ([Fig 2](#pone.0152448.g002){ref-type="fig"}). When stratified by ethnicity, similar results were obtained in Asians subgroup. Cancer risks were remarkably reduced in TT vs. CC (OR = 0.75, 95% CIs: 0.61--0.92, P = 0.006, *I*^*2*^ = 24.1%) and TT vs. CT+CC (OR = 0.75, 95% CIs: 0.62--092, P = 0.005, *I*^*2*^ = 10.8%) genetic models. There were no significant associations in TT+CT vs. CC (OR = 0.94, 95% CIs: 0.74--1.20 P = 0.625, *I*^*2*^ = 69.9%), TC vs. CC (OR = 0.99, 95% CIs: 0.76--1.30, P = 0.959, *I*^*2*^ = 72.4%) and T vs. C (OR = 0.90, 95% CIs: 0.77--1.05, P = 0.190, *I*^*2*^ = 59.1%) ([Fig 3](#pone.0152448.g003){ref-type="fig"}). When considered the source of the control groups, we conducted analysis in population-based subgroup. Also, decreased cancer risks were found in TT vs. CC (OR = 0.71, 95% CIs: 0.61--0.84, P = 0.000, *I*^*2*^ = 7.5%), TT vs. CT+CC (OR = 0.74, 95% CIs: 0.64--0.86, P = 0.000, *I*^*2*^ = 1.9%) and T vs. C (OR = 0.84, 95% CIs: 0.78--0.91, P = 0.000, *I*^*2*^ = 26.5%). However, still we had observed no significant associations in TT+CT vs. CC (OR = 0.85, 95% CIs: 0.72--1.00, P = 0.054, *I*^*2*^ = 52.0%) and TC vs. CC (OR = 0.91, 95% CIs: 0.75--1.10, P = 0.335, *I*^*2*^ = 61.5%) ([Fig 4](#pone.0152448.g004){ref-type="fig"}).

![Forest plots of the *PD-1*.*5* (rs2227981) polymorphism and cancer risk for overall populations (A for TT vs. CC; B for TT vs. CT+CC; C for TT+CT vs. CC; D for TC vs. CC and E for T vs. C).\
The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which was the inverse of the variance). The diamonds represent the pooled ORs and 95% CIs.](pone.0152448.g002){#pone.0152448.g002}

![Forest plots of the *PD-1*.*5* (rs2227981) polymorphism and cancer risk for Asians subgroup (A for TT vs. CC; B for TT vs. CT+CC; C for TT+CT vs. CC; D for TC vs. CC and E for T vs. C).\
The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which was the inverse of the variance). The diamonds represent the pooled ORs and 95% CIs.](pone.0152448.g003){#pone.0152448.g003}

![Forest plots of the *PD-1*.*5* (rs2227981) polymorphism and cancer risk for population-based subgroup (A for TT vs. CC; B for TT vs. CT+CC; C for TT+CT vs. CC; D for TC vs. CC and E for T vs. C).\
The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which was the inverse of the variance). The diamonds represent the pooled ORs and 95% CIs.](pone.0152448.g004){#pone.0152448.g004}

*PD-1*.*9* (rs2227982) and *PD-1* rs7421861 {#sec010}
-------------------------------------------

The *PD-1*.*9* (rs2227982) and *PD-1* rs7421861 polymorphisms were both discussed in four studies, which including 1,961 and 1,975 cases, and 2,390 and 2,403 controls, respectively. Overall, there were no significant associations between either *PD-1*.*9* (rs2227982) ([Fig 5](#pone.0152448.g005){ref-type="fig"}) or *PD-1* rs7421861 ([Fig 6](#pone.0152448.g006){ref-type="fig"}) and cancers in all genetic models and allele (*PD-1*.*9*: TT vs. CC: OR = 1.10, 95% CIs: 0.84--1.45, P = 0.487, *I*^*2*^ = 52.4%; TT vs. CT+CC: OR = 1.04, 95% CIs: 0.89--1.21, P = 0.609, *I*^*2*^ = 15.5%; TT+CT vs. CC: OR = 1.06, 95% CIs: 0.93--1.22, P = 0.399, *I*^*2*^ = 41.6%; TC vs. CC: OR = 1.04, 95% CIs: 0.90--1.20, P = 0.595, *I*^*2*^ = 25.8%; T vs. C: OR = 1.04, 95% CIs: 0.95--1.14, P = 0.393, *I*^*2*^ = 41.5%; *PD-1* rs7421861: CC vs. TT: OR = 0.86, 95% CIs: 0.61--1.23, P = 0.419, *I*^*2*^ = 0.0%; CC vs. CT+TT: OR = 0.84, 95% CIs: 0.59--1.19, P = 0.331, *I*^*2*^ = 0.0%; CC+CT vs. TT: OR = 1.10, 95% CIs: 0.97--1.24, P = 0.137, *I*^*2*^ = 0.0%; CT vs. TT: OR = 1.13, 95% CIs: 0.99--1.28, P = 0.072, *I*^*2*^ = 0.0%; C vs. T: OR = 1.06, 95% CIs: 0.95--1.18, P = 0.322, *I*^*2*^ = 0.0%). All the studies about these two polymorphisms are conducted in Asians. When concerning the control sources, there are two hospital-based and two population-based articles studied about the *PD-1*.*9* (rs2227982) polymorphism, while three hospital-based and one population-based article studied about the *PD-1* rs7421861 polymorphism.

![Forest plots of the *PD-1*.*9* (rs2227982) polymorphism and cancer risk for overall populations (A for TT vs. CC; B for TT vs. CT+CC; C for TT+CT vs. CC; D for TC vs. CC and E for T vs. C).\
The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which was the inverse of the variance). The diamonds represent the pooled ORs and 95% CIs.](pone.0152448.g005){#pone.0152448.g005}

![Forest plots of the *PD-1* rs7421861 polymorphism and cancer risk for overall populations (A for CC vs. TT; B for CC vs. CT+TT; C for CC+CT vs. TT; D for CT vs. TT and E for C vs. T).\
The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which was the inverse of the variance). The diamonds represent the pooled ORs and 95% CIs.](pone.0152448.g006){#pone.0152448.g006}

*PD-1*.*3* (rs11568821) {#sec011}
-----------------------

There are four studies containing 1,280 cases and 1,236 controls discussed this polymorphism. All of these studies are population-based and conducted in Asians. Overall, a significantly decreased cancer risk was found in AG vs. GG genetic model (OR = 0.79, 95% CIs: 0.65--0.96, P = 0.021, *I*^*2*^ = 0.0%). Interestingly, an increased cancer risk was found in AA vs. AG+GG genetic model (OR = 2.25, 95% CIs: 1.30--3.87, P = 0.004, *I*^*2*^ = 48.5%). In addition, there were no associations between cancer risk and AA vs. GG (OR = 1.72, 95% CIs: 0.50--5.94, P = 0.394, *I*^*2*^ = 59.4%), AA+AG (OR = 0.92, 95% CIs: 0.63--1.32, P = 0.638, *I*^*2*^ = 68.4%) vs. GG or A vs. G (OR = 1.02, 95% CIs: 0.64--1.62, P = 0.945, *I*^*2*^ = 85.5%) ([Fig 7](#pone.0152448.g007){ref-type="fig"}).

![Forest plots of the *PD-1*.*3*(rs11568821) polymorphism and cancer risk for overall populations (A for AA vs. GG; B for AA vs. AG+GG; C for AA+AG vs. GG; D for AG vs. GG and E for A vs. G).\
The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which was the inverse of the variance). The diamonds represent the pooled ORs and 95% CIs.](pone.0152448.g007){#pone.0152448.g007}

Publication bias {#sec012}
----------------

We performed both funnel plots and Egger's tests for all genetic models and allele to assess the publication bias. Our results showed all the funnel plots were symmetrical distribution that suggested absence of publication bias ([S1](#pone.0152448.s001){ref-type="supplementary-material"}--[S6](#pone.0152448.s006){ref-type="supplementary-material"} Figs). Also the results were supported by the Egger's tests ([S1 Table](#pone.0152448.s008){ref-type="supplementary-material"}).

Discussion {#sec013}
==========

It is known to us that *PD-1* is an immune gene with potent inhibitory effects on immune cells. As an important gene for the "fine turning" of T lymphocyte activation and proliferation to affect host anti-tumor immunity, *PD-1* merits more investigations. Many studies have reported that over expression of *PD-1* is associated with poor prognosis in several tumors, which including breast, cervical, gastric, esophageal cancers and non-small cell lung cancer (NSCLC) \[[@pone.0152448.ref007]--[@pone.0152448.ref010], [@pone.0152448.ref039]\]. *PD-1* is expressed on tumor specific T cells, when interacts with PD-Ls, expressed on tumor and immune cells, could extensively restricts host anti-tumor immunity and creates antitumor suppressive milieu \[[@pone.0152448.ref040], [@pone.0152448.ref041]\]. Accordingly, it has been considered that blockade of *PD-1*-PDLs interaction as an immunotherapy procedure to conquer immune-suppression associated with cancer condition \[[@pone.0152448.ref041]\]. Recently, some studies had investigated the relationship between *PD-1* polymorphisms and various cancers including breast, gastric, colorectal, lung and liver cancer, et al. However, the results are controversial. So we performed this meta-analysis to discuss the associations between *PD-1* polymorphisms and cancer risk.

Previously, Mamat U et al. performed a meta-analysis \[[@pone.0152448.ref042]\] discussed the association between *PD-1*.*5* (rs2227981) polymorphism and cancer risks. Their results showed no association between *PD-1*.*5* (rs2227981) polymorphism and total cancer risk, but revealed an increased digestive system tumor risk. However, we found that they wrongly included one study researched about the *PD-1*.*3* (rs11568821) polymorphism and colon cancer risk \[[@pone.0152448.ref043]\] in their meta-analysis. Hence, it may significantly affect their total results and digestive system tumor subgroup results. In addition, they only enrolled six studies which including a wrong one and discussed the cancer risks with one polymorphism. By contrast, our meta-analysis included 12 relevant published studies and discussed the cancer risks with four polymorphisms. Moreover, our meta-analysis included higher numbers of the cases and controls than the prior one. In addition, we evaluated the quality of studies by Newcastle-Ottawa Scale and all the studies we included were met high quality, while the prior meta-analysis did not conduct any study quality assessment. So, our meta-analysis made a more convincing and detailed evaluation than the prior study did. All the characteristics and results of the present study for *PD-1*.*5* (rs2227981) polymorphism compared with the prior meta-analysis were summarized in [Table 3](#pone.0152448.t003){ref-type="table"}.

10.1371/journal.pone.0152448.t003

###### Characteristics and results of the present study compared with the previous meta-analysis.
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                                             No. of studies   No. of cases   No. of controls   Overall results                        
  --------------------------- -------------- ---------------- -------------- ----------------- ----------------- ------- ------- ---- ----
  *PD-1*.*5* (rs2227981)      TT vs. CC      6                7              1,415             3,395             1,611   2,912   −    \+
                              TT vs. CT+CC                                                                                       −    \+
                              TT+CT vs. CC                                                                                       −    −
                              TC vs. CC                                                                                          −    −
                              T vs. C                                                                                            −    \+
  Asians Subgroup             TT vs. CC      NA               6              NA                2,095             NA      2,102   NA   \+
                              TT vs. CT+CC                                                                                       NA   \+
                              TT+CT vs. CC                                                                                       NA   −
                              TC vs. CC                                                                                          NA   −
                              T vs. C                                                                                            NA   −
  Population-based Subgroup   TT vs. CC      NA               6              NA                3,273             NA      2,746   NA   \+
                              TT vs. CT+CC                                                                                       NA   \+
                              TT+CT vs. CC                                                                                       NA   −
                              TC vs. CC                                                                                          NA   −
                              T vs. C                                                                                            NA   −

+, positive result; −, negative result; NA, not available

In recent years, the application of the genome-wide association study (GWAS) in many types of diseases has exploded and lots of the GWASs about cancer risk were published. However, there is no GWAS focused on the *PD-1* polymorphisms and cancer risk. Therefore, our research mainly concerned on the case-control studies. In this study, association between *PD-1*.*5* (rs2227981), *PD-1*.*9* (rs2227982), *PD-1* rs7421861 or *PD-1*.*3* (rs11568821) and cancers risk were examined in all genetic models and allele, and all the results were summarized in [Table 4](#pone.0152448.t004){ref-type="table"}. Concerning *PD-1*.*5*, our results showed a significant decreased cancer risks both in TT vs. CC and TT vs. CT+CC genetic models for overall population, Asians and population-based controls, also significant decreased cancer risk was found in T vs. C allele for overall population. *PD-1*.*5* located in exon 5, is a synonymous polymorphism that does not change final amino acid sequence of the protein. Thus these significant associations between *PD-1*.*5* and cancers probably may be *PD-1*.*5* variation linkage disequilibrium with other *PD-1* gene polymorphisms that may lead to alter the *PD-1* expression level \[[@pone.0152448.ref044]\]. Recently, Zhang Hua et al. \[[@pone.0152448.ref029]\] reported that the frequencies of CC genotype and C allele were higher in breast cancer patients than those in control individuals in Chinese population, and CC genotype and C allele may play a potential risk role in breast cancer. Consistently, our results indicated that in *PD-1*.*5*, TT genotype may reduce the cancers risk.

10.1371/journal.pone.0152448.t004

###### Summary of meta-analyses of *PD-1* polymorphisms and cancer risk.
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  Group                         Contrast       No. of studies   No. of cases   No. of controls   OR (95% CI)        Statistical method   *I*^*2*^%   *P*-value
  ----------------------------- -------------- ---------------- -------------- ----------------- ------------------ -------------------- ----------- -----------
  ***PD-1*.*5* (rs2227981)**                                                                                                                         
   Overall                      TT vs. CC      7                3,395          2,912             0.72(0.62--0.85)   Fixed                14.0        0.000
                                TT vs. CT+CC                                                     0.75(0.65--0.87)   Fixed                0.0         0.000
                                TT+CT vs. CC                                                     0.91(0.75--1.10)   Random               65.6        0.343
                                TC vs. CC                                                        0.97(0.78--1.19)   Random               68.2        0.759
                                T vs. C                                                          0.88(0.78--0.99)   Random               53.6        0.040
   Asians Subgroup              TT vs. CC      6                2,095          2,102             0.75(0.61--0.92)   Fixed                24.1        0.006
                                TT vs. CT+CC                                                     0.75(0.62--0.92)   Fixed                10.8        0.005
                                TT+CT vs. CC                                                     0.94(0.74--1.20)   Random               69.9        0.625
                                TC vs. CC                                                        0.99(0.76--1.30)   Random               72.4        0.959
                                T vs. C                                                          0.90(0.77--1.05)   Random               59.1        0.190
   Population-based Subgroup    TT vs. CC      6                3,273          2,746             0.71(0.61--0.84)   Fixed                7.50        0.000
                                TT vs. CT+CC                                                     0.74(0.64--0.86)   Fixed                1.90        0.000
                                TT+CT vs. CC                                                     0.85(0.72--1.00)   Random               52.0        0.054
                                TC vs. CC                                                        0.91(0.75--1.10)   Random               61.5        0.335
                                T vs. C                                                          0.84(0.78--0.91)   Fixed                26.5        0.000
  ***PD-1*.*9* (rs2227982)**    TT vs. CC      4                1,961          2,390             1.10(0.84--1.45)   Random               52.4        0.487
   Overall                      TT vs. CT+CC                                                     1.04(0.89--1.21)   Fixed                15.5        0.609
                                TT+CT vs. CC                                                     1.06(0.93--1.22)   Fixed                41.6        0.399
                                TC vs. CC                                                        1.04(0.90--1.20)   Fixed                25.8        0.595
                                T vs. C                                                          1.04(0.95--1.14)   Fixed                41.5        0.393
  ***PD-1* rs7421861**          CC vs. TT      4                1,975          2,403             0.86(0.61--1.23)   Fixed                0.0         0.419
   Overall                      CC vs. CT+TT                                                     0.84(0.59--1.19)   Fixed                0.0         0.331
                                CC+CT vs. TT                                                     1.10(0.97--1.24)   Fixed                0.0         0.137
                                CT vs. TT                                                        1.13(0.99--1.28)   Fixed                0.0         0.072
                                C vs. T                                                          1.06(0.95--1.18)   Fixed                0.0         0.322
  ***PD-1*.*3* (rs11568821)**   AA vs. GG      4                1,280          1,236             1.72(0.50--5.94)   Random               59.4        0.394
   Overall                      AA vs. AG+GG                                                     2.25(1.30--3.87)   Fixed                48.5        0.004
                                AA+AG vs. GG                                                     0.92(0.63--1.32)   Random               68.4        0.638
                                AG vs. GG                                                        0.79(0.65--0.96)   Fixed                0.0         0.021
                                A vs. G                                                          1.02(0.64--1.62)   Random               85.5        0.945

We also investigated the *PD-1*.*9* (rs2227982) and *PD-1* rs7421861 polymorphisms. It has been identified that *PD-1*.*9*, located in exon 5, is a non-synonymous SNP of *PD-1*, resulting the amino acid substitution from valine to alanine during protein synthesis, which probably lead to different structures and different functions of *PD-1*. As for *PD-1* rs7421861, it is situated in intron 1 where a number of regulatory elements and splicing control elements exist \[[@pone.0152448.ref045], [@pone.0152448.ref046]\]. Therefore, due to the disruption of the splice site or alteration of the mRNA secondary structure, *PD-1* rs7421861 may induce aberrant splicing, and further result in translational prevention \[[@pone.0152448.ref047]--[@pone.0152448.ref049]\]. However, we failed to find the associations between cancer risk and the *PD-1*.*9* (rs2227982) or *PD-1* rs7421861 in all genetic models and alleles. The limited sample size may be an important reason of the results, and we should treat the results with caution. Further studies are also needed to determine the function of these two polymorphisms.

In addition, we discussed the *PD-1*.*3* (rs11568821) polymorphism in our meta-analysis. The *PD-1*.*3* polymorphism was a guanine (G) to adenine (A) single nucleotide polymorphism (SNP) at nucleotide +7146 in the *PD-1* intron 4. A region of *PD-1* intron 4 was described as an enhancer-like structure containing binding sites for several transcription factors \[[@pone.0152448.ref050]\]. Existing study has shown that the *PD-1*.*3* polymorphism in this region may affect the binding of the runt-related transcription factor 1 (RUNX1) and alter the transcriptional regulation and the efficiency of *PD-1* gene \[[@pone.0152448.ref051]\]. Moreover, the research indicated that the presence of A allele of *PD-1*.*3* polymorphism disrupted the binding site for RUNX1 transcription factors and resulted the impairment of *PD-1* inhibitory effect and higher lymphocyte activity \[[@pone.0152448.ref050]\]. Hence, the A allele of *PD-1*.*3* polymorphism may have increased tumor immunity capacity and decreased the susceptibility of cancers. Consistently, our results of *PD-1*.*3* (rs11568821) polymorphism showed a decreased cancer risk in GA vs. GG, but an increased cancer risk was found in AA vs. AG+GG. Besides, no dramatic associations were found between AA vs. GG, AA+AG vs. GG genetic models or A vs. G allele and cancer risk. However, large scale and more rigorous analytical studies will be required to confirm the association between *PD-1*.*3* polymorphism and cancer risk.

There are some limitations should be addressed in this meta-analysis. First of all, the limited number of participants for *PD-1*.*3* (rs11568821) polymorphism may lead to insufficient statistical power to explore the real association. Secondly, the heterogeneities were significant in some genetic models and alleles for *PD-1*.*5* (rs2227981) and *PD-1*.*3* (rs11568821) polymorphisms. When we performed subgroup analyses stratified by ethnicity and control source, the heterogeneities in some subgroups were decreased or removed while in some subgroups were still existed. Thirdly, lacking of the original data limited our further evaluation of potential gene-gene, gene-environment, or even different polymorphism loci of the same gene, which all may affect cancer risk.

In summary, our meta-analysis suggested that the *PD-1*.*5* (rs2227981) polymorphism is associated with significantly decreased cancer risks both in TT vs. CC and TT vs. CT+CC genetic models, no matter for overall population, Asians subgroup or population-based subgroup, also the decreased cancer risk was found in T vs. C allele for overall population. No associations were found between the cancer risks and *PD-1*.*9* (rs2227982) or *PD-1* rs7421861 in all genetic models and allele. In addition, for *PD-1*.*3* (rs11568821) polymorphism, we found different cancer susceptibility between GA vs. GG and AA vs. AG+GG genetic models, and no associations between AA vs. GG, AA+AG vs. GG genetic models or A vs. G allele and cancer risk. However, our results firstly revealed a significantly decreased risk between *PD-1* polymorphisms and cancers, even though the data may be limited. Hence, large scale, well-designed epidemiological studies will be required to confirm our findings in the future.
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###### Funnel plot for publication bias of the *PD-1* rs7421861 polymorphism and cancer risk for overall populations (A for CC vs. TT; B for CC vs. CT+TT; C for CC+CT vs. TT; D for CT vs. TT and E for C vs. T).
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###### 

Click here for additional data file.

###### Funnel plot for publication bias of the *PD-1*.*3*(rs11568821) polymorphism and cancer risk for overall populations (A for AA vs. GG; B for AA vs. AG+GG; C for AA+AG vs. GG; D for AG vs. GG and E for A vs. G).
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